[go: up one dir, main page]

MX2019001633A - Proteina derivada de la seda para el tratamiento de la inflamacion. - Google Patents

Proteina derivada de la seda para el tratamiento de la inflamacion.

Info

Publication number
MX2019001633A
MX2019001633A MX2019001633A MX2019001633A MX2019001633A MX 2019001633 A MX2019001633 A MX 2019001633A MX 2019001633 A MX2019001633 A MX 2019001633A MX 2019001633 A MX2019001633 A MX 2019001633A MX 2019001633 A MX2019001633 A MX 2019001633A
Authority
MX
Mexico
Prior art keywords
silk
treatment
inflammation
protein derived
effective amount
Prior art date
Application number
MX2019001633A
Other languages
English (en)
Inventor
D Lawrence Brian
W Infanger David
Original Assignee
Silk Tech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Silk Tech Ltd filed Critical Silk Tech Ltd
Publication of MX2019001633A publication Critical patent/MX2019001633A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43563—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects
    • C07K14/43586—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects from silkworms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02—Prostheses implantable into the body
    • A61F2/14—Eye parts, e.g. lenses or corneal implants; Artificial eyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/01—Hydrolysed proteins; Derivatives thereof
    • A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Insects & Arthropods (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Cardiology (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

En el presente documento se describen procedimientos para reducir la inflamación mediante la administración de una cantidad eficaz de proteínas obtenidas de la seda (SDP) o una fracción de las mismas a un sujeto que tiene una afección inflamatoria. Los procedimientos incluyen el tratamiento de afecciones inflamatorias y heridas, incluyendo heridas de la córnea, que comprende la administración tópica de una cantidad eficaz de material de SDP como se describe en el presente documento.
MX2019001633A 2016-08-12 2017-08-12 Proteina derivada de la seda para el tratamiento de la inflamacion. MX2019001633A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662374532P 2016-08-12 2016-08-12
US201662407863P 2016-10-13 2016-10-13
US201762467697P 2017-03-06 2017-03-06
PCT/US2017/046659 WO2018031973A1 (en) 2016-08-12 2017-08-12 Silk-derived protein for treating inflammation

Publications (1)

Publication Number Publication Date
MX2019001633A true MX2019001633A (es) 2019-09-18

Family

ID=61163249

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019001633A MX2019001633A (es) 2016-08-12 2017-08-12 Proteina derivada de la seda para el tratamiento de la inflamacion.

Country Status (11)

Country Link
US (2) US11242367B2 (es)
EP (1) EP3496662A4 (es)
JP (1) JP2019531334A (es)
KR (1) KR102275012B1 (es)
CN (1) CN109862851A (es)
AU (1) AU2017310520A1 (es)
CA (1) CA3033507A1 (es)
MX (1) MX2019001633A (es)
NZ (1) NZ751231A (es)
SG (1) SG11201901137UA (es)
WO (1) WO2018031973A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9394355B2 (en) 2014-08-20 2016-07-19 Silk Technologies, Ltd. Fibroin-derived protein composition
WO2019094702A1 (en) 2017-11-10 2019-05-16 Cocoon Biotech Inc. Ocular applications of silk-based products
EP3910096A4 (en) * 2019-01-09 2023-05-24 Spiber Inc. MODIFIED FIBROIN
WO2020247594A1 (en) 2019-06-04 2020-12-10 Cocoon Biotech Inc. Silk-based products, formulations, and methods of use
KR102374291B1 (ko) * 2019-09-10 2022-03-14 강릉원주대학교산학협력단 천연 포졸란을 포함하는 사료 첨가제 조성물
JP7670704B2 (ja) * 2019-11-15 2025-04-30 シルク テクノロジーズ、リミテッド 絹由来タンパク質の安定した配合物
IT201900023142A1 (it) * 2019-12-05 2021-06-05 Sifi Spa Composizione topica oculare contenente metaboliti della fermentazione di lactobacillus
KR102194995B1 (ko) * 2020-09-16 2020-12-28 장혜란 진단을 위한 개선된 건조체액의 안정화 조성물 및 이의 응용방법
US12161693B2 (en) 2021-04-14 2024-12-10 Cocoon Biotech Inc. Methods of making stable silk fibroin formulations
JP2024538181A (ja) * 2021-10-18 2024-10-18 エボルブド バイ ネイチャー， インコーポレイテッド 絹によって刺激されたコラーゲン及びクローディン－１発現、並びに絹によって刺激された抗炎症効果
CN114685825B (zh) * 2022-03-22 2023-02-28 浙江大学 一种蚕丝蛋白共晶凝胶的制备方法及其产品和应用
CN117288958B (zh) * 2023-09-18 2025-08-29 福州大学附属省立医院 一种检测蛋白质的试剂在制备诊断精神分裂症攻击性行为的产品中的应用

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5931520B2 (ja) 1979-03-22 1984-08-02 カネボウ株式会社 絹フイブロインペプチド水溶液の製造法
IL101850A (en) 1991-06-13 1996-01-31 Janssen Pharmaceutica Nv 11-(4-Piperidinyl)-imidazo (2,1-b) (3) benzazepine derivatives their preparation and pharmaceutical compositions containing them
CA2125060C (en) 1993-07-02 1999-03-30 Henry P. Dabrowski Ophthalmic solution for artificial tears
JPH0767686A (ja) 1993-09-06 1995-03-14 Shinano Kenshi Co Ltd 低分子量の絹フィブロインペプチドの製造方法
US5760004A (en) 1994-11-21 1998-06-02 Protein Polymer Technologies, Inc. Chemical modification of repetitive polymers to enhance water solubility
JP3449658B2 (ja) 1994-12-21 2003-09-22 杏林製薬株式会社 安定性に優れた８−アルコキシキノロンカルボン酸水和物並びにその製造方法
US5895645A (en) 1995-01-31 1999-04-20 Bausch & Lomb Incorporated Opthalmic solution for artificial tears
JPH08295697A (ja) 1995-04-26 1996-11-12 Kanebo Ltd 高濃度絹フィブロイン水溶液の製造方法
AU2022599A (en) 1997-12-31 1999-07-19 Kimberly-Clark Worldwide, Inc. Method of reducing molecular weights and polydispersity indices of polymers of ethylene oxide
FR2774588B1 (fr) 1998-02-11 2000-05-05 Oreal Composition cosmetique ou dermatologique contenant au moins une proteine de soie d'arachnides naturelle, recombinante ou un analogue
CN1133432C (zh) 1998-08-21 2004-01-07 千寿制药株式会社 含水液体药物组合物
JP2000143472A (ja) 1998-11-10 2000-05-23 Hiroshi Akai 紫外線吸収機能を有する化粧剤
US20020172693A1 (en) 2000-03-31 2002-11-21 Delong Michell Anthony Compositions and methods for treating hair loss using non-naturally occurring prostaglandins
NZ521185A (en) 2000-07-14 2005-02-25 Allergan Inc Compositions containing alpha-2-adrenergic agonist components
US8858961B2 (en) 2000-07-14 2014-10-14 Allergan, Inc. Compositions containing alpha-2-adrenergic agonist components
KR20030023700A (ko) 2000-07-14 2003-03-19 알러간, 인코포레이티드 치료활성 성분을 함유하고 용해도가 증강된 조성물
US20030206897A1 (en) 2000-09-13 2003-11-06 The Procter & Gamble Company Cosmetic compositions
IT1316885B1 (it) 2000-10-02 2003-05-13 Consorzio Per Gli Studi Uni Procedimento per la preparazione di un tessuto non tessuto in fibroinadi seta.
CN1277584C (zh) 2001-10-25 2006-10-04 康涅狄格大学 生物活性物质,制备生物活性物质的方法及其使用方法
WO2003045336A1 (en) 2001-11-29 2003-06-05 National Institute Of Agrobiological Sciences Emulsifier and process for producing the same
US7351404B2 (en) 2002-02-04 2008-04-01 Allergan, Inc. Method of enhancing hair growth
US7642258B2 (en) 2002-04-19 2010-01-05 Allergan, Inc. Combination of brimonidine and timolol for topical ophthalmic use
US7030149B2 (en) 2002-04-19 2006-04-18 Allergan, Inc. Combination of brimonidine timolol for topical ophthalmic use
US7842780B2 (en) 2003-01-07 2010-11-30 Trustees Of Tufts College Silk fibroin materials and use thereof
US7060260B2 (en) 2003-02-20 2006-06-13 E.I. Du Pont De Nemours And Company Water-soluble silk proteins in compositions for skin care, hair care or hair coloring
KR20040077553A (ko) * 2003-02-28 2004-09-04 독립행정법인농업생물자원연구소 견 단백질로부터 세포 생육 펩티드의 추출과 이용
US7115388B2 (en) 2003-03-14 2006-10-03 National Institute Of Agrobiological Sciences Production of functional polypeptides originating from silk protein and use thereof
US20050196370A1 (en) 2003-03-18 2005-09-08 Zhi-Jian Yu Stable ophthalmic oil-in-water emulsions with sodium hyaluronate for alleviating dry eye
CA2562415C (en) 2003-04-10 2015-10-27 Tufts University Concentrated aqueous silk fibroin solutions free of organic solvents and uses thereof
CA2468664C (en) 2003-06-03 2012-03-06 Allergan, Inc. Ketorolac tromethamine compositions for treating or preventing ocular pain
JP2007501799A (ja) 2003-08-07 2007-02-01 アラーガン、インコーポレイテッド 眼内に医薬を送達するための組成物ならびにその調製方法および使用方法
US20050059583A1 (en) 2003-09-15 2005-03-17 Allergan, Inc. Methods of providing therapeutic effects using cyclosporin components
EP1682537B1 (en) 2003-11-05 2012-03-28 SARcode Bioscience Inc. Modulators of cellular adhesion
US20050202097A1 (en) 2004-03-12 2005-09-15 Melbj Holdings, Llc, Florida Lubricant for the ocular surface
EP1609801A1 (en) 2004-06-25 2005-12-28 Technische Universität München Proteins of natural origin and materials made therefrom
US10010574B2 (en) 2004-07-31 2018-07-03 Brainguard Co., Ltd. Silk peptide for improving neuroprotective and neurofunctional effects and a method of its preparation
US8569367B2 (en) 2004-11-16 2013-10-29 Allergan, Inc. Ophthalmic compositions and methods for treating eyes
WO2010102078A1 (en) 2009-03-04 2010-09-10 Allergan, Inc. Enhanced bimatoprost ophthalmic solution
US7851504B2 (en) 2005-03-16 2010-12-14 Allergan, Inc. Enhanced bimatoprost ophthalmic solution
EP2444079B1 (en) 2005-05-17 2016-11-30 SARcode Bioscience Inc. Compositions and Methods for Treatment of Eye Disorders
JP5748392B2 (ja) 2005-10-05 2015-07-15 コモンウェルス サイエンティフィック アンド インダストリアル リサーチ オーガナイゼーション 絹タンパク質
DK3150209T3 (da) 2006-03-31 2019-10-28 Vistakon Pharmaceuticals Llc Okulære allergibehandlinger
WO2007130364A2 (en) 2006-05-01 2007-11-15 Riolan Technologies, Inc. Compositions, methods, and kits for treating dry eye
WO2008109138A1 (en) 2007-03-07 2008-09-12 Grune Guerry L Spf compositions
CN104013598A (zh) 2007-05-29 2014-09-03 塔夫茨大学信托人 利用超声处理使丝纤蛋白凝胶化的方法
CN101194666A (zh) 2007-11-28 2008-06-11 吴江市方霞企业信息咨询有限公司 蚕蛹丝素蛋白功能性食品
WO2009088119A1 (en) 2008-01-07 2009-07-16 Bioleaders Corporation Composition for preventing or treating dry eye syndrome comprising poly-gamma-glutamic acid
US7842714B2 (en) 2008-03-03 2010-11-30 Allergan, Inc. Ketorolac tromethamine compositions for treating ocular pain
WO2009139817A2 (en) 2008-04-15 2009-11-19 Sarcode Corporation Crystalline pharmaceutical and methods of preparation and use thereof
US8569730B2 (en) 2008-07-08 2013-10-29 Sandisk 3D Llc Carbon-based interface layer for a memory device and methods of forming the same
WO2010141133A2 (en) 2009-03-04 2010-12-09 Trustees Of Tufts College Silk fibroin systems for antibiotic delivery
US20110014287A1 (en) 2009-04-20 2011-01-20 Altman Gregory H Silk Fibroin Hydrogels and Uses Thereof
MX358504B (es) 2009-06-05 2018-08-21 Allergan Inc Lagrimas artificiales y usos terapeuticos.
IN2012DN00445A (es) 2009-07-14 2015-05-15 Tufts College
WO2011050175A1 (en) 2009-10-21 2011-04-28 Sarcode Corporation Crystalline pharmaceutical and methods of preparation and use thereof
WO2011109691A2 (en) 2010-03-05 2011-09-09 Trustees Of Tufts College Silk-based ionomeric compositions
US8309689B2 (en) 2010-05-20 2012-11-13 Taipei Medical University High yield dialysis-free process for producing organosoluble regenerated silk fibroin
CA2839719A1 (en) 2010-06-17 2011-12-22 Tufts University / Trustees Of Tufts College Silk optical particles and uses thereof
US20140193466A1 (en) 2011-06-07 2014-07-10 Cornell University Silk compositions and methods of using same
CN102860969A (zh) 2011-07-07 2013-01-09 刘畅 一种大豆眼霜
JP2015508104A (ja) 2012-02-22 2015-03-16 トラスティーズ オブ タフツ カレッジ 治療薬の眼への送達のための組成物および方法
US9056063B2 (en) 2012-03-13 2015-06-16 James E. Hanson Natural sunscreen composition
US20150079012A1 (en) 2012-04-20 2015-03-19 Trustees Of Tufts College Silk fibroin-based personal care compositions
SI3715345T1 (sl) 2012-07-25 2024-07-31 Bausch + Lomb Ireland Limited Priprava zaviralca lfa-1
WO2014127007A1 (en) 2013-02-12 2014-08-21 Seryx Biomedical, Inc. Ophthalmic formulation derived from silk protein
MX367597B (es) 2013-03-15 2019-08-28 Patheon Softgels Inc Cápsulas a base de seda.
EP3412682B1 (en) 2013-03-15 2022-08-31 Trustees Of Tufts College Low molecular weight silk compositions and stabilizing silk compositions
CN103239707A (zh) 2013-05-22 2013-08-14 江苏紫石化工科技有限公司 治疗近视的滴眼液
EP4509520A3 (en) 2013-09-30 2025-10-22 Evolved by Nature, Inc. Silk protein fragment compositions and articles manufactured therefrom
AU2014353110B2 (en) 2013-11-19 2018-05-10 Cornell University Tissue scaffold materials for tissue regeneration and methods of making
US9394355B2 (en) * 2014-08-20 2016-07-19 Silk Technologies, Ltd. Fibroin-derived protein composition
US10758645B2 (en) * 2014-12-17 2020-09-01 Tufts University Injectable, flexible hydroxyapatite-silk foams for osteochondral and dental repair
CA3020342A1 (en) * 2016-04-08 2017-11-23 Cornell University A method to enhance wound healing using silk-derived protein

Also Published As

Publication number Publication date
KR20190042608A (ko) 2019-04-24
JP2019531334A (ja) 2019-10-31
EP3496662A1 (en) 2019-06-19
US11242367B2 (en) 2022-02-08
NZ751231A (en) 2025-08-29
SG11201901137UA (en) 2019-03-28
CN109862851A (zh) 2019-06-07
CA3033507A1 (en) 2018-02-15
AU2017310520A1 (en) 2019-03-21
WO2018031973A1 (en) 2018-02-15
EP3496662A4 (en) 2019-10-30
US20190169243A1 (en) 2019-06-06
KR102275012B1 (ko) 2021-07-07
US20220332773A1 (en) 2022-10-20

Similar Documents

Publication Publication Date Title
MX2019001633A (es) Proteina derivada de la seda para el tratamiento de la inflamacion.
CL2018001897A1 (es) Composiciones para modular la expresión de sod-1 (divisional solicitud 201602509)
CL2018001685A1 (es) Compuestos heterociclicos como inmuno moduladores.
IL268850A (en) Combinations of a 4-pyrimidinesulfamide derivative with active ingredients for the treatment of endothelin related diseases
EA201890725A1 (ru) Агонисты фарнезоидного х-рецептора и их применение
EA201990598A1 (ru) Высококонцентрированные низковязкие препараты ингибирующего masp-2 антитела, наборы и способы
MX2019001481A (es) Derivado de oxopicolinamida, metodo de preparacion y uso farmaceutico del mismo.
MX2018005315A (es) Composiciones y metodos para el tratamiento del cancer.
CL2021001395A1 (es) Compuestos derivados de panteteínas cíclicas; composición farmacéutica que los comprende; y su uso para aumentar las concentraciones de acetil-coa, para el tratamiento de cáncer, enfermedad inflamatoria, enfermedad neurodegenerativa, esclerosis múltiple, entre otras enfermedades.
CR20160222U (es) Formas solidas de acido { [ -(3- clorofenil) -3- hidroxipiridin -2-carbonil] amino} acetico, composiciones, y usos de las mismas
SV2018005714A (es) Composiciones y metodos para disminuir la expresion de tau
CR20190394A (es) Compuestos de inhibidores de autotaxina
CR20150637A (es) Tratamiento de enfermedades miopaticas y neurodegenerativas por agregación de proteina mediante administración parenteral
CL2019001749A1 (es) Uso de anticuerpos anti-esclerostina en el tratamiento de osteogenesis imperfecta.
EA202090014A1 (ru) Гетероароматические соединения в качестве ингибиторов ванина
NI201600070A (es) Inhibidores tetracíclicos de autotaxina
IL280664A (en) 2-arylbenzimidazoles as ppargc1a activators for treating neurodegenerative diseases
EA201792571A1 (ru) Терапевтическое применение l-4-хлорокинуренина
CL2021002483A1 (es) Compuestos y composiciones como moduladores de la señalización tlr
EA201692402A1 (ru) Лекарственные формы для местного применения и их использование
EA201892265A1 (ru) Способы лечения офтальмологических заболеваний
EA202091112A1 (ru) Сокристаллы, фармацевтические композиции на их основе и способы лечения, предусматривающие их применение
BR112018015367A2 (pt) carreadores oromucosais de nanofibra para tratamento terapêutico
CO2019009020A2 (es) Derivados de pirazol como inhibidores de bromodominio.
AR101486A1 (es) Anticuerpos anti proteína similar a angiopoyetina 4 y métodos de uso